Press Releases See All 01/09/2023 Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues 01/05/2023 Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate 01/03/2023 Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference Stories & Perspectives Filter by: Filter by: All Advocates & Innovators Culture & Community Inside the Science Patient Voices Filter by: AllAdvocates & InnovatorsCulture & CommunityInside the SciencePatient Voices Patient Voices Creating pathways to LGMD genetic diagnosis: Spotlight on LGMD Grant Award recipient Advocates & Innovators Ensuring the Safety of Clinical Trial Participants: Meet Eddie Darton, M.D. Advocates & Innovators Dragging tomorrow into today: Meet Rachael Potter, Ph.D. Inside the Science Understanding external controls and their importance to clinical trials for rare diseases Inside the Science Meaningful measure: Understanding the NSAA, an important Duchenne functional-assessment tool Culture & Community What’d you do this summer? Our summer interns share lessons learned Culture & Community Pride Proud: What belonging feels like and why representation matters Advocates & Innovators A Conversation with CFO Ian Estepan, recipient of the 2022 CFO of the Year award from the Boston Business Journal Inside the Science Seroprevalence: What patients should know about pre-existing antibodies to gene therapy Inside the Science Patient registries: A catalyst for developing new therapies for rare diseases Inside the Science Measurements Used in Clinical Trials for Duchenne Muscular Dystrophy – an Overview Advocates & Innovators How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center Culture & Community Giving Thanks for Our Employees’ Incredible Dedication: Six Employees Explain Why Sarepta is a Top Place to Work Inside the Science Welcome to GT‐FAQ! Advocates & Innovators Expanding Access to Newborn Screening for Those with Rare Diseases Patient Voices Patiently Waiting Advocates & Innovators From Art to Science: How One Sarepta Scientist Brings the Arts into the Lab Patient Voices Advocacy Community Unites to Support Families Culture & Community How Sarepta Infused its Corporate Brand with Urgency and Optimism on Behalf of Patients Inside the Science What’s in a name? A lot, for the limb-girdle muscular dystrophy community. Media Library Sarepta Corporate Logos, Images & Fact Sheets View All Press Contact Tracy Sorrentino Executive Director, Public Relations Sarepta Therapeutics, Inc.[email protected]617-274-4052
01/09/2023 Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
01/05/2023 Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
Inside the Science Understanding external controls and their importance to clinical trials for rare diseases
Inside the Science Meaningful measure: Understanding the NSAA, an important Duchenne functional-assessment tool
Advocates & Innovators A Conversation with CFO Ian Estepan, recipient of the 2022 CFO of the Year award from the Boston Business Journal
Inside the Science Seroprevalence: What patients should know about pre-existing antibodies to gene therapy
Inside the Science Measurements Used in Clinical Trials for Duchenne Muscular Dystrophy – an Overview
Advocates & Innovators How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center
Culture & Community Giving Thanks for Our Employees’ Incredible Dedication: Six Employees Explain Why Sarepta is a Top Place to Work
Culture & Community How Sarepta Infused its Corporate Brand with Urgency and Optimism on Behalf of Patients